Journal of Proteomics ( IF 2.8 ) Pub Date : 2023-07-06 , DOI: 10.1016/j.jprot.2023.104958
Meng-Meng Wang 1 , Min-Tao Gai 2 , Bao-Zhu Wang 3 , Maitudi Maituxun 3 , Gulinazi Yesitayi 3 , Bang-Dang Chen 2 , Xiang Ma 3
|
Background and aims
Acute aortic dissection (AAD) is a serious life-threatening cardiovascular condition. It is necessary to find rapid and accurate biomarkers for the diagnosis of AAD. This study aimed to determine the efficacy of serum amyloid A1 (SAA1) in the diagnosis and prediction of long-term adverse events in AAD.
Materials and methods
Four-dimensional label-free quantification (4D-LFQ) technique was used to identify the differentially expressed proteins (DEPs) in aortic tissues of AAD. After comprehensive analysis, SAA1 was identified as a potential biomarker of AAD. ELISA was used to confirm the expression of SAA1 in serum of AAD patients. Moreover, the source of SAA1 in serum was explored by constructing AAD mouse model.
Results
A total of 247 DEPs were identified, of which 139 were upregulated while 108 were downregulated. SAA1 was nearly 6.4-fold and 4.5-fold upregulated in AAD tissue and serum. ROC curve and Kaplan-Meier survival curve confirmed the good efficacy of SAA1 for the diagnosis and prediction of long-term adverse events in AAD. In vivo experiments revealed that SAA1 was mainly derived from the liver when AAD occurred.
Conclusion
SAA1 can be used as a potential biomarker for AAD with effective diagnostic and prognostic value.
Significance
Despite the advances in medical technology in recent years, the mortality rate of acute aortic dissection (AAD) is still high. It is still challenging for clinicians to diagnose AAD patients on time and reduce the mortality rate. In this study, 4D-LFQ technology was used to identify serum amyloid A1 (SAA1) as a potential biomarker of AAD and was verified in subsequent work. The results of this study determined the efficacy of SAA1 in the diagnosis and prediction of long-term adverse events in patients with AAD.
中文翻译：
SAA1作为急性主动脉夹层新型生物标志物的诊断和预后价值
背景和目标
急性主动脉夹层（AAD）是一种严重危及生命的心血管疾病。有必要寻找快速、准确的生物标志物来诊断 AAD。本研究旨在确定血清淀粉样蛋白 A1 (SAA1) 在诊断和预测 AAD 长期不良事件中的功效。
材料和方法
采用四维无标记定量（4D-LFQ）技术来鉴定 AAD 主动脉组织中的差异表达蛋白（DEP）。经过综合分析，SAA1被确定为AAD的潜在生物标志物。采用ELISA法证实AAD患者血清中SAA1的表达。此外，通过构建AAD小鼠模型，探讨了血清中SAA1的来源。
结果
总共鉴定出 247 个 DEP，其中 139 个上调，108 个下调。SAA1 在 AAD 组织和血清中上调近 6.4 倍和 4.5 倍。ROC曲线和Kaplan-Meier生存曲线证实了SAA1对于AAD诊断和长期不良事件预测的良好疗效。体内实验表明，AAD发生时SAA1主要来源于肝脏。
结论
SAA1可作为AAD的潜在生物标志物，具有有效的诊断和预后价值。
意义
尽管近年来医疗技术不断进步，但急性主动脉夹层（AAD）的死亡率仍然很高。如何及时诊断AAD患者并降低死亡率对临床医生来说仍然是一个挑战。本研究采用4D-LFQ技术鉴定血清淀粉样蛋白A1（SAA1）作为AAD的潜在生物标志物，并在后续工作中得到验证。这项研究的结果确定了 SAA1 在诊断和预测 AAD 患者长期不良事件方面的功效。
京公网安备 11010802027423号